Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01035879 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes | PHASE2 | COMPLETED | 100 | — | — | Dec 1, 2009 | Aug 1, 2010 | Apr 17, 2015 | 14 | United States, Georgia +1 |
| Arm | Type | Description |
|---|---|---|
| MBX-2982 25 mg | EXPERIMENTAL | - |
| MBX-2982 100 mg | EXPERIMENTAL | - |
| MBX-2982 300 mg | EXPERIMENTAL | - |
| Sitagliptin 100 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2982 | DRUG | tablets and capsule once daily |
| Sitagliptin | DRUG | tablets and capsule once daily |
| placebo | DRUG | tablets and capsule once daily |
Inclusion Criteria: * History of type 2 diabetes of at least 3 months duration * Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone) * HbA1c 7.0-8.5% (inclusive) at sc...